Background-Peptic ulcers with active bleeding or a non-bleeding visible vessel require aggressive endoscopic treatment.
Aims-To determine whether endoscopic adrenaline injection alone or contact probe therapy following injection is a suitable treatment for peptic ulcer bleeding.
Methods-total of 96 patients with active bleeding or non-bleeding visible vessels received adrenaline alone, bipolar electrocoagulation alone, or combined treatment (n=32 in each group).
Initial haemostasis was not achieved in one patient in the adrenaline group, two in the gold probe group, and two in the injection gold probe group (p>0.1).
Rebleeding episodes were fewer in the injection gold probe group (2130,6.7%) than in the gold probe group (9130,30%, p=0.04) and in the adrenaline group (11/31,35.5%, p=0.01).
Treatment failure (other therapy required) was rarer in the injection gold probe group (4/32,12.5%) than in the adrenaline group (12/32,37.5%, p=0.04).
The volume of blood transfused after entry of the study was less in the injection gold probe group (mean 491 ml) than in the adrenaline group (1548 ml, p<0.0001) and the gold probe group (1105 ml, p<0.01).
Duration of hospital stay, numbers of patients requiring urgent surgery, and death rate were not statistically different among the three groups. (...)
Mots-clés Pascal : Hémorragie, Gastrointestinal, Protocole thérapeutique, Adrénaline, Voie abord, Laparoscopie, Electrocoagulation bipolaire, Etude comparative, Hémostase, Efficacité traitement, Homme, Chine, Asie, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Vasoconstricteur, Hémostatique, Traitement instrumental, Economie santé
Mots-clés Pascal anglais : Hemorrhage, Gastrointestinal, Therapeutic protocol, Epinephrine, Surgical approach, Laparoscopy, Bipolar electrocoagulation, Comparative study, Hemostasis, Treatment efficiency, Human, China, Asia, Digestive diseases, Gastric disease, Intestinal disease, Cardiovascular disease, Vascular disease, Vasoconstrictor agent, Hemostatic, Instrumentation therapy, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0246592
Code Inist : 002B26F. Création : 16/11/1999.